Table 1.
Patient characteristics and effectiveness of TMZ+Bev
Best overall
response |
Progression-free
survival (months) |
Overall survival (months) |
Prognosis | ||||||||
Age | Sex | Primary organ | Metastases | Choi | RECIST | Choi | RECIST | ||||
41 | M | meninges | pancreas, lung | SD | SD | 26.4 | 29.6 | 64.4+ | alive | ||
47 | F | meninges | pelvis, bone | SD | SD | 8.9 | 18.6 | 20.7+ | alive | ||
52 | F | meninges | liver, lung | SD | SD | 9.4 | 9.4 | 59.0 | died | ||
75 | M | pleura | lymph nodes, spleen, liver |
PR | PR | 15.8 | 15.8 | 17.3+ | alive |